MAGNOLIA DIAGNOSTICS LLC NPI 1922551399

NPI Details

MAGNOLIA DIAGNOSTICS, LLC is a clinical medical laboratory in Dallas, TX. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. MAGNOLIA DIAGNOSTICS, LLC NPI is 1922551399. The provider is registered as an organization entity type and is a multi-specialty group.

The provider's business location address is:

4245 N CENTRAL EXPY STE 420
DALLAS, TX
ZIP 75205-566
Phone: (972) 707-9929

The provider's authorized official is John Bains .
The authorized official title is President and has the following contact phone number (205) 356-6790.

The CLIA number assigned to this NPI record is 45D2114310 - independent with a certificate type of Certificate of Accreditation.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0004)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Detection test by nucleic acid for multiple organisms, amplified probe(s) technique (HCPCS:87801)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Detection test by nucleic acid for multiple types influenza virus (HCPCS:87502)
• Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique (HCPCS:87581)
• Detection test by nucleic acid for legionella pneumophila (water borne bacteria), amplified probe technique (HCPCS:87541)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique (HCPCS:87486)
• Detection test by nucleic acid for respiratory syncytial virus, amplified probe technique (HCPCS:87634)
• Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets (HCPCS:87631)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Identification of organisms by genetic analysis, amplified probe technique (HCPCS:87150)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 6-11 targets (HCPCS:87506)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Stool analysis for blood, by fecal hemoglobin determination by immunoassay (HCPCS:82274)
• Detection test by nucleic acid for clostridium difficile, amplified probe technique (HCPCS:87493)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)

The enumeration date for this NPI number is 8/2/2016 and was last updated on 9/18/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: